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Abstract
Cytotoxic chemotherapy, hormonal therapy and molecular
targeted therapy are the three major classes of drugs used to
treat breast cancer. Imaging modalities such as computed to-
mography (CT), magnetic resonance imaging (MRI), 18F-
FDG positron emission tomography (PET)/CTand bone scin-
tigraphy each have a distinct role in monitoring response and
detecting drug toxicities associated with these treatments. The
purpose of this article is to elucidate the various systemic
therapies used in breast cancer, with an emphasis on the role
of imaging in assessing treatment response and detecting
treatment-related toxicities.
Teaching Points
• Cytotoxic chemotherapy is often used in combination with
HER2-targeted and endocrine therapies.
• Endocrine and HER2-targeted therapies are recommended
in hormone-receptor- and HER2-positive cases.
• CT is the workhorse for assessment of treatment response in
breast cancer metastases.
• Alternate treatment response criteria can help in interpreting
pseudoprogression in metastasis.
• Unique toxicities are associated with cytotoxic chemothera-
py and with endocrine and HER2-targeted therapies.
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Introduction
A paradigm shift has occurred over the past few decades in the
systemic (non-surgical and non-radiation) treatment of breast
cancer, with treatment regimens evolving from single-agent
chemotherapy to those involving hormonal therapy, combina-
tion chemotherapy and molecular-targeted therapy (MTT) [1].
Much of this evolution can be attributed to a better under-
standing of the molecular complexity of breast cancer. Recent
studies have revealed that there are several molecular pheno-
types of breast cancer, based on receptor expression [2]. The
major subtypes of these include luminal A, luminal B, HER2-
positive and triple-negative (TN) breast cancer [2]. The risk of
recurrence, disease management and outcome of these major
subtypes vary significantly.
Anti-oestrogen therapy is an integral part of hormone re-
ceptor (HR)-positive cancers, and acts by inhibiting the
growth of oestrogen-sensitive tumour cells [1]. In HER2/
neu-positive cancer, MTTs directed to the HER2 receptor in-
hibit signal transduction pathways involved in oncogenesis
[1]. MTTs have also changed the course of treatment in
triple-negative breast cancer (TNBC). The increased use of
these drugs in clinical practice warrants the attention of radi-
ologists who must be familiar with the patterns of tumour
response to systemic therapy and the complications associated
with them. Accordingly, the purpose of this article is to pro-
vide a comprehensive review of the various cytotoxic,
hormonal and biologic agents used in breast cancer in
neoadjuvant, adjuvant and metastatic settings, with an
emphasis on the role of imaging in assessing treatment
response and drug toxicities.
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Systemic treatment in breast cancer: an overview
Systemic treatment in breast cancer includes cytotoxic chemo-
therapy, hormonal therapy, molecular-targeted therapy or a
combination of these (Table 1). Temporally, systemic treat-
ment can be stratified into neoadjuvant, adjuvant and metasta-
tic settings, with each having a distinct goal [1]. The objective
of neoadjuvant treatment is to downgrade the tumour in order
to facilitate breast-conserving surgery and to guide post-
operative chemotherapy. Adjuvant therapy is now standard
practice for reducing both systemic and local recurrence, with
most guidelines recommending systemic treatment for node-
positive disease and tumours larger than 1 cm, irrespective of
other tumour characteristics.
The commonly used cytotoxic drugs are taxanes (paclitaxel
and docetaxel), cyclophosphamide, eribulin, capecitabine, cis-
platin and anthracyclines (doxorubicin and epirubicin).
Taxanes and anthracyclines are the mainstay in first-line treat-
ment of breast cancer in the adjuvant, neoadjuvant and meta-
static settings, and are often used with HER2-targeted thera-
pies in HER2-positive breast cancer and with hormonal ther-
apy in HR-positive breast cancer. Anthracycline-based regi-
mens have shown greater efficacy than non-anthracycline
based regimens in HER2-positive tumours [1]. National Com-
prehensive Cancer Network (NCCN) guidelines recommend
adjuvant cytotoxic chemotherapy for all tumours greater than
1 cm, and consideration for use in tumours greater than 0.6 cm
or in instances of microinvasion, regardless of molecular char-
acteristics [1]. The drugs used in adjuvant therapy can also be
used in a neoadjuvant setting, while single-agent therapy is
preferred for metastatic disease in order to reduce toxicity in
aggressive regimens.
Hormonal therapy is recommended for most women with
HR-positive breast cancer. Tamoxifen, a selective oestrogen
receptor modulator (SERM), acts as an antagonist of the
oestrogen receptor (ER) in breast tissue and as agonist in the
uterine endometrium [3]. Recently, another class of hormonal
agents, called aromatase inhibitors (AIs), has shown superior
efficacy to tamoxifen in the metastatic, neoadjuvant and adju-
vant settings in postmenopausal women. Anastrozole,
letrozole and exemestane are the three most widely used of
these drugs. These agents work by reducing the aromatization
of peripheral androgens into oestrogen [4]. Neoadjuvant hor-
monal therapy has shown an equivalent to superior response
compared to neoadjuvant chemotherapy in HR-positive breast
cancer. Studies have demonstrated greater rates of breast-
Table 1 Systemic treatment in breast cancer
Drugs Mechanism of action Side effects
Chemotherapy
Anthracycline (doxorubicin and epirubicin) Inhibits DNA and RNA synthesis Cardiotoxicity, typhlitis, bone marrow suppression
Taxanes (paclitaxel and docetaxel) Inhibits mitosis by stabilization of
microtubule polymer
Fluid retention, neutropenic enterocolitis and
typhlitis, drug-associated pneumonitis
Cyclophosphamide Interferes with DNA replication by
forming intrastrand and interstrand
DNA cross-links
Hemorrhagic cystitis, Drug associated
pneumonitis, diarrhoea
Capecitabine Irreversibly inhibits thymidylate synthase Neurotoxicity, mucositis, hand-foot syndrome
Eribulin Inhibits mitosis by interfering with
growth of microtubule
Neutropenia, diarrhoea, anaemia, peripheral
nHER2athy
Hormonal therapy
Tamoxifen Selectively blocks estrogen receptor
blockage




(anastrozole, letrozole, and exemestane)
Blocks estrogen production Osteoporosis, arthralgia
Fulvestrant Estrogen receptor antagonist Elevation of liver enzymes, oedema
Molecular-targeted therapy
Trastuzumab, pertuzumab Interferes with the HER2/neu receptor Cardiotoxicity, pulmonary toxicity
Lapatinib Interrupts the HER2/neu and epidermal
growth factor receptor (EGFR) pathways
Rash, diarrhoea, liver dysfunction,
Bevacizumab Inhibits vascular endothelial growth
factor (VEGF)
Hepatic steatosis, pancreatitis, cholecystitis,
infection
Trastuzumab emtansine Antibody-drug conjugate binds to HER2
receptors and enters the cell and
releases the cytotoxic agent emtansine
Hepatotoxicity, thrombocytopenia
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conserving surgery in postmenopausal oestrogen
receptor-positive breast cancer patients on neoadjuvant
hormonal therapy versus neoadjuvant chemotherapy [5].
Furthermore, higher rates of breast-conserving surgery
have been demonstrated in patients treated with AIs ver-
sus tamoxifen [6]. Endocrine therapy has a better toxicity
profile and is preferred when chemotherapy cannot be
tolerated. Another anti-oestrogen agent, fulvestrant, is
an ER antagonist, and unlike tamoxifen, has no agonist
effects. Fulvestrant was approved for second-line use in
postmenopausal women with HR-positive metastatic
breast cancer with disease progression following treat-
ment with an anti-oestrogen [7]. Luteinizing hormone-
releasing hormone (LHRH) agonists (goserelin,
leuprolide), progestins (megestrol acetate), androgens
(fluoxymesterone) and high-dose oestrogen (ethinyl es-
tradiol) are other hormonal therapies used in the adjuvant
and metastatic setting in breast cancer [1].
Trastuzumab (Herceptin) is a monoclonal antibody
that targets cancer cells that over-express a protein called
HER2 that is involved in cell growth, differentiation and
blood vessel formation (angiogenesis). Up to 20 % of
women with breast cancer have tumours with high levels
of HER2, and many trials have demonstrated better
disease-free survival with the addition of trastuzumab in
combination with standard first-line chemotherapy for the
treatment of HER2-positive breast cancer [8, 9].
Pertuzumab is another HER2 receptor inhibitor (HER2
dimerization inhibitor) that has been approved by the
United States Food and Drug Administration (FDA) for
use in metastatic breast cancer. Other targeted agents
currently being studied in breast cancer include other
HER2-directed agents (lapatinib); HER3 agents, which
inhibit dimerization of the HER2 receptor and thus deac-
tivate the tyrosine kinase pathway; vascular endothelial
growth factor (VEGF) inhibitors (bevacizumab); poly
(ADP-ribose) polymerase (PARP) inhibitors; and inhibi-
tors of the mammalian target of rapamycin (mTOR) sig-
nalling pathway [10, 11]. Lapatinib is an orally active
dual tyrosine kinase inhibitor that affects both HER2/
neu and epidermal growth factor receptor (EGFR) path-
ways. It is being evaluated in patients with refractory
CNS metastases from HER2-positive metastatic breast
cancer, given its ability to achieve therapeutic levels in
cerebrospinal fluid [12]. Studies such as the phase III
CLEOPATRA [Clinical Evaluation Of Pertuzumab and
Trastuzumab] trial have demonstrated a benefit in
progression-free survival with the use of a dual anti-
HER2 blockade in the metastatic setting over a single
anti-HER2 agent [13]. The NCCN guidelines now rec-
ommend trastuzumab and pertuzumab (in combination)
in HER2-positive metastatic disease in combination with
a taxane [1].
Role of imaging in the assessment of treatment
response
Imaging plays a key role in monitoring response to treatment
(Table 2). According to the NCCN guidelines, assessment of
disease is most accurate when an abnormal finding is serially
followed with the same imaging modality. There is no general
consensus on the optimal frequency of restaging scans. Comput-
ed tomography (CT) is generally recommended every 2–4 cycles
in patients on chemotherapy and every 2–6months in patients on
endocrine therapy [1]. However, if the patient develops new or
worsening signs and symptoms, appropriate imaging should be
pursued immediately. Patients enrolled in clinical trials tend to be
restaged more frequently to determine drug efficacy.
Multidetector computed tomography (MDCT)
MDCT is theworkhorse for monitoringmetastatic breast cancer.
Liver metastases occur in more than 50 % patients with breast
cancer, and are seen as hypodense lesions. Restaging MDCT
scans following systemic treatment typically show a reduction
in size of the hypodense lesions in patients responding to treat-
ment (Fig. 1). Non contrast images are useful in finding accurate
tumour volume on follow-up MDCT [14]. At our institute, we
routinely perform non-contrast imaging of the abdomen in all
breast cancer patients, as breast cancer metastases can some-
times remain occult on the portal venous phase and can be better
followed on non-contrast images on restaging scans [14]. The
use of multiphasic CT with arterial and venous phase imaging
has been shown to increase the detection rate of hypervascular
liver metastasis, including those from breast, renal, and thyroid
cancers, carcinoid tumours and melanoma [15]. There have
been no large prospective studies analyzing the diagnostic accu-
racy of MDCT in assessing treatment response in liver metasta-
sis from breast cancer. The Response Evaluation Criteria in
Solid Tumours (RECIST) is the most widely accepted set of
objective treatment response criteria [16, 17]. A recent retro-
spective study by He et al., however, showed that RECIST
was inadequate for assessing response to targeted therapies in
breast cancer liver metastasis. In their study of 39 patients with
68 liver lesions, while treatment with cytotoxic chemotherapy
showed a decrease in both size and density of liver metastases,
treatment with targeted therapies alone did not, although 2-year
survival was better [18].
A classic finding seen in treated breast cancer metastases is
hepatic capsular retraction, or Bpseudocirrhosis^ (Fig. 1). In
patients undergoing chemotherapy, pseudocirrhosis has been
documented as a form of treatment response, described as
capsular retraction secondary to shrinkage and retraction of
tumours. This finding occurs more often in larger than smaller
hepatic lesions, suggesting that intrinsic pathologic character-
istics such as tumour growth or fibrosis, rather than tumour
response alone, may contribute to capsular retraction [19].
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Treatment with molecular-targeted drugs can reduce the en-
hancement of hepatic metastatic lesions compared to adjacent
l iver parenchyma. This phenomenon, known as
pseudoprogression, with the appearance of apparent new le-
sions or transient enlargement of existing lesions is frequently
seen on post-treatment follow-up CT examinations (Fig. 2)
[20]. Similarly, lytic osseous metastatic lesions show osteo-
blastic response after systemic therapy. Restaging scans may
show apparent new sclerotic lesions due to osteoblastic treat-
ment response, which can be confused as new bone metasta-
ses (pseudoprogression) (Fig. 3) [21, 22]. Clinical and bio-
chemical correlation (tumours markers) helps to assess treat-
ment response in such cases.
Thoracic metastases in breast cancer can involve pulmo-
nary parenchyma, airways, pleura and thoracic lymph nodes
[23]. Imaging patterns of lung parenchymal metastases from
breast cancer include solitary or multiple lung nodules,
endobronchial nodules, lymphangitic carcinomatosis and
air–space consolidation. Pleural disease from breast cancer
usually manifests as pleural nodularity, thickening and effu-
sions. Metastatic parenchymal nodules are generally solid,
spheric or ovoid in shape, sharply marginated, and located
mostly in the periphery of the lung in contrast to other aetiol-
ogies such as infection or inflammation [23]. However, a sol-
itary pulmonary nodule appearing in a patient with breast
cancer is not always suggestive of metastatic disease, as more
than 50 % of the nodules may have aetiologies such as
primary lung tumour or other benign lesions, and histological
confirmation is necessary [24]. Pulmonary nodules respond to
systemic treatment with a reduction in size. Cavitation of pul-
monary nodules is uncommonly seen as secondary to both
cytotoxic chemotherapy and newer anti-angiogenic agents.
To prevent misclassification as disease progression, alterna-
tive methods of measuring cavitary lesions (i.e. exclusion of
the air component during measurement) have been described
in the primary lung cancer literature [25].
Magnetic resonance Imaging (MRI)
Breast MRI In the neoadjuvant setting, breast magnetic res-
onance (MR) imaging is a useful tool for monitoring response
to chemotherapy, and is superior to clinical examination, ul-
trasound andmammography [26]. The tumour size correlation
coefficient between MRI and pathologic analysis is very high
(more than 0.9) compared to that of clinical examination and
mammography (around 0.7) [26]. MRI has demonstrated high
sensitivity (96 %) and accuracy (89 %) for the detection of
residual disease after neoadjuvant chemotherapy [27]. Various
studies have shown that the accuracy of MRI in this setting
varies with the molecular subtype of breast cancer, the pattern
of enhancement on pre-treatment MRI and the nuclear grade
[27]. MRI has demonstrated higher accuracy in assessing
treatment response and size changes in tumours with
HER2+ or triple-negative status, and lower accuracy with
Table 2 Imaging of metastatic breast cancer
Location Imaging modalities Remarks
CNS MRI • Modality of choice due to superior soft tissue resolution
• DWI and perfusion MRI: help to differentiate between tumour recurrence and post-radiation changes
PET/CT • Differentiation between tumour recurrence and post-radiation changes
Lung X-ray • Initial screening modality
• Less sensitive than CT for detection of pulmonary metastasis
CT • Modality of choice for detection of pulmonary metastasis and mediastinal adenopathy
• Evaluation of treatment response as well as detecting various pulmonary toxicities associated
with radiation and systemic chemotherapy
Liver CT • Multiphasic CTwith non contrast, arterial and venous phase imaging is most commonly used
for evaluation of treatment response in patients undergoing systemic therapies
• Non-contrast images are useful for better delineation of lesions
MRI • Better characterization of suspicious lesion on CT
• Hepatocyte-specific contrast agents: for detection of smaller lesions (<1 cm) and differentiation
between metastasis and FNH
• Better sensitivity than CT in presence of hepatic steatosis
Bone X-ray • Usually the first modality in the case of musculoskeletal signs and symptoms
CT • Assessment of axial skeleton during follow-up CT studies in patients undergoing systemic therapies
MRI • Superior contrast resolution and useful for evaluation of extraosseous soft tissue extension
Tc 99m MDP bone scintigraphy • Evaluation of asymptomatic patients to detect occult bone metastases
PET/CT • More sensitive than scintigraphy for detecting lytic metastases and marrow involvement
• Differentiation of flare phenomena vs. true disease worsening
MRI magnetic resonance imaging, PET positron emission tomography, CT computed tomography,MDP methylene diphosphonate, FNH focal nodular
hyperplasia
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luminal-type breast cancer, low nuclear grade and diffuse non-
mass-like enhancement on initial MRI [27, 28]. Dynamic
contrast-enhanced MRI, in addition to morphological analy-
sis, offers the advantage of evaluating enhancement kinetics,
which correlate with angiogenic changes in response to neo-
adjuvant therapy (Fig. 4) [29].
Liver MRI Superior soft tissue characterization renders MR
imaging particularly helpful in the evaluation of liver
Fig. 1 65-year-old woman with triple-positive breast cancer with
multiple hepatic metastases treated with systemic chemotherapy. a
Axial contrast-enhanced CT image before start of chemotherapy shows
multiple low-attenuation hepatic metastatic lesions (arrows), more
prominent in left lobe. b Axial contrast-enhanced CT image after 4
months of chemotherapy shows volume loss and surface nodularity in
left lobe of liver (arrow), with capsular retraction in segment IV
(arrowhead) and decrease in size of metastatic lesions. c Axial contrast-
enhanced CT image after 10 months of chemotherapy shows marked
atrophy of left lobe of liver (arrow), with further decrease in size of
metastatic lesions in right lobe
Fig. 2 58-year-old woman with estrogen receptor-positive metastatic
breast cancer treated with trastuzumab. a Axial contrast-enhanced CT
image of the abdomen demonstrates a subcentimeter hypodense lesion
in the liver (arrow) and ascites. b Follow-up scan after 3 months of
treatment shows increase in the size of the liver metastasis with
concurrent decrease in the ascites. Patient continued therapy due to
decrease in tumour markers. c Repeat scan 2 months later shows
decreased size of liver metastasis. The transient increase in the size of
the metastasis on the interim scan (b) was due to decreased enhancement
of the lesion suggestive of pseudoprogression
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metastases. Dynamic contrast-enhanced MRI has greater than
90 % sensitivity in the identification of hepatic metastases,
compared to contrast-enhanced CT at around 80 % [30].
Hepatocyte-specific contrast agents, including gadoxetate
disodium (Eovist/Primovist; Bayer HealthCare, Leverkusen,
Germany) and gadobenate dimeglumine (MultiHance; Bracco
Diagnostics Inc., Princeton, NJ, USA), are excreted through a
combination of biliary and renal routes [31]. Gadoxetate
disodium has approximately 50% biliary excretion in patients
with normal liver and renal function, and the addition of a
hepatobiliary phase in dynamic-contrast MRI has shown in-
creased sensitivity (more than 10 %) in detecting metastatic
lesions over dynamic MRI alone (Fig. 5) [32]. These agents
are particularly useful in detecting small metastases, less than
1 cm in size [33], and for differentiation of metastatic lesions
from focal nodular hyperplasia (FNH) [34]. In the assessment
of treatment response, MRI with in-phase and out-of-phase
imaging can be more effective for the evaluation of lesions
in the setting of chemotherapy-induced hepatic steatosis,
which can obscure liver metastases [20]. Diffusion-weighted
MRI has been shown in a few studies to predict early response
to treatment in breast cancer [35].
Brain MRI MRI is the best modality for localizing brain
metastases and assessing response to treatment (Fig. 6). In
patients with a good prognosis, local control with surgery
and/or radiation treatment (either stereotactic or whole-brain
radiation therapy) can be pursued. Measuring the response is
often difficult, as the appearance of post-treatment changes
can mimic recurrent or residual pathology. Determining
whether a ring-enhancing lesion at the site of the treated tu-
mour represents treatment response (radiation necrosis or
granulation tissue surrounding a resection cavity) versus re-
currence can be particularly challenging. The chronology of
the appearance of the lesion can be helpful, as radiation ne-
crosis typically appears within 4 months and resolves after 2–
3 years [36]. Advanced MRI techniques such as diffusion and
perfusion MRI are helpful for differentiating between tumour
recurrence and post-treatment changes [37]. Recurrent tu-
mours show restricted diffusion, whereas post-treatment
changes have high signal intensity on apparent diffusion co-
efficient (ADC) maps. Metastatic lesions on perfusion MR
will typically demonstrate increased relative cerebral blood
volume (rCBV), while radiation necrosis usually shows de-
creased rCBV [36].
18F-FDG PET/CT
Positron emission tomography (PET)/CT is a useful diagnos-
tic modality in the event of equivocal findings on conventional
staging techniques, especially in patients with locally ad-
vanced or metastatic disease [1]. In the neoadjuvant setting,
a decrease in maximum standardized uptake value (SUVmax)
of 60 % from baseline has shown up to 96 % specificity in
predicting pathologic complete response (pCR) after just one
course of chemotherapy (Fig. 7) [38]. This contributes impor-
tant prognostic information, as patients with pCR have signif-
icantly higher disease-free and overall survival rates than non-
responders. PET/CT is also valuable for detecting metabolic
changes following treatment with antineoplastic agents. Prior
to PET/CT, methods for monitoring therapeutic effectiveness
were limited to physical exam or conventional imaging, thus
relying on physical and morphological information. PET/CT
is effective for monitoring physiological response after one
treatment, prior to pathologic confirmation at the time of sur-
gery, and thus decisions regarding the continuation or modifi-
cation of therapy can be made early in the treatment course
[39]. The pooled sensitivity and specificity of FDG-PET/CT
in predicting histopathologic response in primary breast can-
cer is 81 and 79 %, respectively [40]. Similar to that of MRI,
Fig. 3 82-year-old woman with estrogen and progesterone receptor-
positive breast cancer with bony metastases being treated with systemic
chemotherapy. a Coronal pretreatment CT image of the lumbar spine and
pelvis in bone window settings shows a predominantly lytic lesion
involving L3 and L5 vertebrae (arrows) and left iliac bone
(arrowhead). b Coronal CT image of the lumbar spine and pelvis after
4 months of therapy shows progressive sclerotic changes involving L3
and L5 vertebrae (arrow) and left iliac (arrowhead) lesions representative
of treatment effect. This response is in agreement with patient’s improved
clinical status and tumour marker levels
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the performance of FDG-PET/CT in predicting pathologic
complete response is better in HER2-positive and triple-
negative tumours than in the luminal subtype [40]. In the
metastatic setting, the sensitivity and specificity of FDG-
PET/CT is 93 and 82 %, respectively [41]. The degree of
reduction in FDG uptake in metastatic lesions after the first
cycle of chemotherapy has been shown in some studies to
differentiate responders from non-responders [41]. In evalua-
tion of osseous metastasis, FDG-PET/CT can help in identi-
fying viable metastases, as treated metastases become FDG-
negative but remain osteoblastic on CT [41]. In cases of brain
metastasis, FDG-PET is useful for differentiating between
post-radiation necrosis and tumour recurrence [42]. One study
found that dual-phase FDG-PET imaging of the brain was
superior to the standard single-phase FDG-PET in differenti-
ating recurrent metastasis from post-treatment necrosis [43].
99mTc methylene diphosphonate (MDP) bone
scintigraphy
Bone is the most common site of breast cancer metastasis.
Bone scintigraphy is the most widely used modality for de-
tecting bone metastases, and demonstrates osteoblastic activ-
ity as areas of increased radiotracer uptake. However, certain
characteristic false-negative and false-positive findings on
scintigraphy should be kept in mind in assessing treatment
response. Scintigraphy sometimes demonstrates an apparent
worsening of abnormalities, known as the Bflare phenomenon,
^ characterized by increased activity in known lesions or new
lesions during the first 3 months after treatment as a result of
bone repair (Fig. 8) [44]. This finding should not be confused
with progression of disease, and should be followed up with
another bone scan in 4 to 6 months. A finding that persists
beyond 6 months, however, is more likely indicative of dis-
ease progression. The apparent worsening or new sclerotic
osseous lesions should be interpreted with caution, and should
not be considered new or progressive disease, particularly in
the setting of improving tumour markers and clinical status
and the absence of other bone progression. The concept of
increased osteoblastic healing reaction was introduced as a
criterion for treatment response by the M.D. Anderson Cancer
Center in 2004 [45]. In the revised criteria, CT and MRI are
included as imaging modalities for assessing treatment re-
sponse in bony metastases. The appearance of peripheral scle-
rosis around initial lytic lesions or sclerosis of previously un-
detectable lesions on CTor radiographs is considered a partial
response. The rapid regression of lesions on scintigraphy was
excluded as a partial response, as this finding may represent
progression of lytic bony lesions. Bone scintigraphy is not
sensitive for lytic osseous metastases given the low amount
or absence of osteoblastic activity in these lesions. 18F-FDG
PET is more sensitive than scintigraphy in detecting lytic me-
tastases and marrow involvement [46]. The recently proposed
PERCIST (PET Response Criteria in Solid Tumours)
Fig. 4 36-year-old woman with
invasive lobular carcinoma in the
right breast. a Axial contrast-
enhanced T1-weighted MR image
before start of neoadjuvant
chemotherapy shows diffuse skin
thickening and edema involving
the right breast, with multiple
enhancing masses (arrowheads)
and enlarged right axillary lymph
nodes (arrow). b, c Corresponding
color map and enhancement
kinetic curve demonstrate intense
enhancement and washout
consistent with malignancy.
d Axial contrast-enhanced T1-
weightedMR image after 4months
of therapy shows interval
resolution of skin thickening
and breast masses, with marked
decrease in size of axillary lymph
nodes (arrow). e, f Corresponding
color map and enhancement curve
demonstrate nearly complete
resolution of the breast mass
and axillary modes
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guidelines involve the role of FDG PET in treatment response,
with an emphasis on change in tumour metabolism after ther-
apy over anatomically based criteria [47].
Complications associated with treatment: the role
of imaging
Cytotoxic agents
CT is also helpful in monitoring treatment-related complica-
tions. Pulmonary toxicity is a common drug-related compli-
cation seen with taxanes and methotrexate. CT findings in-
clude pulmonary infiltrates presenting in early onset as bilat-
eral reticular, ground-glass or consolidative opacities, pulmo-
nary oedema, and pleural effusions, and as fibrosis in late
disease (Fig. 9) [48]. Pulmonary infiltrates, however, are a
non-specific finding, and can also result from disease progres-
sion and infection; thus clinical factors should also be taken
into consideration.
Neutropenic enterocolitis and typhlitis (neutropenic entero-
colitis of the cecum) are the most common GI side effects of
chemotherapy, and are associated with several cytotoxic
breast cancer drugs including doxorubicin, docetaxel, pacli-
taxel and platinum agents. CT findings include colonic wall
thickening and oedema and/or necrosis, pericolonic fat
stranding, ascites, pneumatosis intestinalis, and free air in
the setting of bowel necrosis and perforation. While most
frequently seen in the right colon, any colonic or small bowel
segment can be involved. Because rapidly dividing GI muco-
sal cells are also vulnerable to cytotoxic agents, GI ulceration,
which may further lead to perforation, is another treatment
complication most commonly associated with doxorubicin
and taxanes. Pneumatosis intestinalis may be observed with
cyclophosphamide, doxorubicin, cisplatin and docetaxel [49].
Fig. 5 46-year-old woman with metastatic hormone receptor-positive
breast cancer. a Axial fat-suppressed T1-weighted MR image in venous
phase after administration of intravenous gadopentetate dimeglumine
(Magnevist) shows ill-defined hyperenhancement in segment III of left
lobe of liver (arrow) and focal hyper-enhancing lesion in segment VII of
right lobe of liver. b Axial fat-suppressed T1-weighted MR image in the
hepatocyte phase (20-min delay) after administration of intravenous
gadoxetate disodium (Eovist) increases conspicuity of the hepatic
lesions in segment III (arrow) and segment VII (arrowhead)
Fig. 6 62-year-old woman with metastatic breast cancer and new
complaint of numbness and tingling in her left hand and left foot. a
Axial contrast-enhanced T1-weighted MR brain image shows
homogenously enhancing lesion within the right lateral aspect of the
medulla (arrow) suggestive of metastasis. b Axial contrast-enhanced
T1-weighted MR brain image after whole-brain radiation and 2 months
of therapy with lapatinib shows significant interval decrease in size of
enhancing lesion in medulla (arrow)
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Fig. 7 36-year-old woman with
invasive lobular carcinoma in the
right breast (same patient as in
Fig. 4). a Coronal maximum-
intensity projection (MIP) 18F-
FDG PET image also performed
prior to start of treatment shows
multiple FDG-avid nodules in the
right breast, with right axillary,
subpectoral, cervical, mediastinal,
and bilateral hilar
lymphadenopathy. Also note the
FDG-avid focus in the sacrum
suggestive of osseous metastasis.
b Coronal maximum-intensity
projection (MIP) 18F-FDG PET
image after 6 months of therapy
shows significant decrease in
FDG-avid lesions suggestive of
response to therapy
Fig. 8 61-year-old woman with breast cancer and osseous metastases
being treated with capecitabine. a Pretreatment bone scan shows
multifocal abnormal radiotracer uptake in calvarium, multiple thoracic
and lumbar vertebrae, and bilateral iliac bones. Focal uptake in left 9th
rib (arrowhead) corresponds to recent traumatic fracture. b Post-
treatment bone scan after 2 months of therapy shows slight increase in
the intensity and extent of radiotracer uptake in the multiple known
metastases, uptake in calvarium, multiple thoracic, and lumbar
vertebrae and bilateral iliac bones. Given the improvement in tumour
markers, this finding was regarded as response to treatment with a
scintigraphic flare phenomenon. Uptake in left 9th rib is decreased
(arrowhead). c Post-treatment bone scan after 4 months of therapy
shows interval decrease in the intensity and extent of radiotracer uptake
in the multiple known metastases. Focal uptake in right 10th rib (arrow)
corresponds to a new traumatic fracture
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Fluid retention, likely due to capillary protein leakage, has
been seen in patients treated with docetaxel, and may manifest
as peripheral oedema and as pleural and pericardial effusions
[50]. Platinum-based agents carry an increased risk of throm-
bus formation [51]. Hemorrhagic cystitis is a well-known
complication of cyclophosphamide, manifesting radiological-
ly as diffuse thickening and nodularity of the bladder wall
secondary to urothelial toxicity. This complication usually oc-
curs early in treatment and is preventable with hydration and
concurrent treatment with mesna, which neutralizes the toxic
metabolic products within the bladder [52].
Hormones
Patients receiving treatment with tamoxifen have an increased
prevalence of endometrial hyperplasia, endometrial polyps
and endometrial carcinoma (Fig. 10). Transvaginal ultrasound
(US) and hysterosonography are useful tools for endometrial
assessment, which is especially helpful in women treated with
tamoxifen. While the agonistic effects of tamoxifen on estro-
gen receptors are beneficial in some tissues—for example, in
lowering serum cholesterol and protecting against bone loss
and cardiovascular disease—its proliferative effects on the
uterine endometrium increase the risk of endometrial cancer
[53]. On transvaginal US, endometrial carcinomas are typical-
ly diffusely or partially echogenic. As many patients treated
on tamoxifen have endometrial thickening and underlying
adenomyosis, poorly defined endometrial thickening is not a
specific sign. Hysterosonography may be of further help in
identifying an irregular, inhomogeneous mass or focal thick-
ening in the endometrium [54]. Lack of distensibility of the
endometrial cavity may also suggest carcinoma. MRI is useful
for the characterization of endometrial abnormalities associat-
ed with tamoxifen therapy [55].
Tamoxifen causes hypercoagulability, increasing the risk of
thromboembolic phenomena and catheter-related thrombosis
(Fig. 8) [56].
Fig. 10 72-year-old woman with metastatic hormone receptor-positive
breast cancer being treated with tamoxifen. a Sagittal contrast-enhanced
CT image of the pelvis shows irregular thickening of the endometrial
lining (arrow) suggestive of endometrial hyperplasia. b Coronal
contrast-enhanced CT image of the pelvis during routine restaging
study shows hypodense filling defect (arrow) in descending branch of
right pulmonary artery suggestive of pulmonary embolism. The patient
had no complaints of chest pain
Fig. 9 69-year-old woman with metastatic hormone receptor-positive,
HER2/neu-positive breast cancer being treated with paclitaxel. Axial
contrast-enhanced lung window CT image before (a) and after (b)
treatment with paclitaxel shows interval appearance of patchy ground-
glass opacities in upper lobes of lungs (arrow in b) suggestive of drug-
associated pneumonitis. Also note the decreased size of left axillary
lymph node (arrowheads in a and b) suggestive of treatment response
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Fatty liver is seen in up to 30 % of patients treated with
tamoxifen (Fig. 11), and can be present as early as 3 months
after initiation of treatment and can persist for more than
4 years after discontinuation [57]. Risk factors for hepatic
changes associated with tamoxifen include preexisting condi-
tions such as diabetes, obesity and hepatic steatosis. Fatty liver
may rarely progress to steatohepatitis and cirrhosis. On ultra-
sound, hepatic steatosis presents as an echogenic liver, while
on CT, the liver appears hypodense in comparison to the
spleen (Fig. 9). On CT, fatty infiltration of the liver may ob-
scure the presence of hypodense metastases. MR is helpful, as
in-phase and out-of-phase imaging will demonstrate intracel-
lular fatty deposition with signal dropout on out-of-phase se-
quences [58].
In postmenopausal women, the primary source of
oestrogen is through conversion from adrenal androgen by
aromatase. AIs prevent the conversion of androgens to estro-
gens, thereby causing a relatively rapid reduction in circulat-
ing oestrogen and an acceleration of bone loss at more than
twice the rate of physiologic postmenopausal loss [59]. Reg-
ular bone marrow density monitoring is thus highly recom-
mended. Bisphosphonates are the first line of therapy for the
prevention and treatment of aromatase inhibitor-associated
bone loss, as women on AIs are at increased risk of fractures
[59].
Molecular-targeted therapies
MTTs have class-specific and drug-specific toxicities. m-TOR
inhibitors such as everolimus are associated with drug-
induced pneumonitis manifesting radiologically as ground-
glass and consolidative opacities [48]. Radiation recall pneu-
monitis refers to an inflammatory reaction in the lungs within
the previously treated radiation field after the start of chemo-
therapy, and can be seen occasionally with HER2 inhibitors
(Fig. 12) [60]. Trastuzumab has been associated with
cardiotoxicity, especially when administered with or after
doxorubicin. The incidence of cardiac dysfunction in patients
receiving trastuzumab ranges from 2 to 28 % [61]. The most
common manifestation of trastuzumab cardiotoxicity is an
asymptomatic decrease in left ventricular ejection fraction
(LVEF) [62]. In contrast to doxorubicin-associated
cardiotoxicity, trastuzumab-induced cardiotoxicity is not relat-
ed to cumulative dose and is often reversible with discontinu-
ation of treatment [63]. Multiple-gated acquisition (MUGA)
scan and echocardiogram are used for determination of LVEF
Fig. 12 67-year-old woman with metastatic HER2/neu-positive breast
cancer being treated with trastuzumab. Patient had prior radiotherapy in
right breast. Axial contrast-enhanced lung window CT image before (a)
and after (b) treatment with trastuzumab shows interval appearance of
peripheral ground-glass opacities in right middle lobe (arrows in b) in
radiation field suggestive of radiation recall pneumonitis
Fig. 11 72-year-old woman with metastatic hormone receptor-positive
breast cancer being treated with tamoxifen. Axial contrast-enhanced CT
image of the pelvis before (a) and after (b) 6 months of treatment with
tamoxifen shows diffuse hypodensity of liver parenchyma on image (b)
compared to image (a) suggestive of diffuse fatty deposition
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in breast cancer patients before and after chemotherapy [64].
The biochemical marker troponin I is also useful for monitor-
ing cardiotoxicity as well as for identifying patients who are at
risk for cardiotoxicity and less likely to recover [65]. Treat-
ment discontinuation is recommended in patients with a great-
er than 16 % drop in LVEF compared to baseline or a decline
in LVEF to below the lower limit of normal, and in patients
who develop symptomatic cardiac failure [66]. Adverse
effects of lapatinib include fatigue, nausea, rash, diarrhoea,
neutropenia, hepatotoxicity, interstitial lung disease and
pneumonitis [67].
Conclusions
Systemic treatment for breast cancer includes a combination
of cytotoxic, hormonal and molecular-targeted therapies in
various stages of treatment. The assessment of response to
these agents on restaging scans has significant a impact on
the patient’s treatment course. Imaging modalities such as
CT, MRI, FDG-PET/CT and bone scintigraphy each have a
distinct role in monitoring response to various treatment strat-
egies. Familiarity with the response patterns on imaging and
toxicities associated with these therapies can enhance the key
role played by radiologists in patient management.
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